Waldencast PLC is not a strong buy for a long-term beginner investor at this time. The stock is currently in a bearish trend with no immediate positive catalysts, weak financial performance, and declining analyst price targets. Given the investor's preference for long-term growth and the absence of strong buy signals, it is better to hold off on investing in this stock until the company's strategic review yields clearer results or the financials improve.
The stock is in a bearish trend with a negatively expanding MACD histogram (-0.0171), an oversold RSI (19.031), and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support levels are at 1.363 and 1.288, with resistance at 1.606 and 1.681.
The company is conducting a strategic review to address market challenges. Growth opportunities exist in Obagi Medical's direct-to-consumer and international channels.
Declining performance in Milk Makeup, particularly in international markets. Elevated costs related to an SEC investigation and strategic review. Slower-than-expected growth and a net loss of $33.5 million in Q4.
In Q4 2025, revenue was $72 million, slightly beating expectations but down 0.1% YoY. The company reported a net loss of $33.5 million. Gross margin increased to 69.91%, but EPS remains negative at -1.51.
Analysts have lowered price targets significantly, with the latest targets ranging from $2 to $2.50. While some analysts maintain a Buy rating, they acknowledge the company's transition period and slower-than-expected growth.